Consultation and Consent

Consent for a collagen-stimulating injectable is a clinical conversation about the exact product, treatment objective, alternatives, expected phases, uncertainties, and material risks. A signed form records that process; it does not replace it.

Explain the intervention precisely

The patient should be able to identify:

the brand and presentation being proposed
the material and whether the product is particulate, hybrid, carrier-based, or manufacturer-described as solubilized
whether it is ready to use or reconstituted
the intended area and whether that use is locally approved or off-label
the expected immediate appearance versus delayed response
the planned course, reassessment points, and reasons a further session may or may not be appropriate

Avoid describing all products as “collagen injections.” The injected product is an implant or device formulation; any later tissue response is not the same as injecting collagen itself.

Set outcome boundaries

Discuss the likely sequence rather than promising one endpoint:

Phase	Counseling point
Immediately after treatment	Fluid, edema, HA, or a carrier may influence appearance
Early follow-up	Initial fullness can change as swelling or fluid resolves
Later assessment	Tissue response and clinical correction are product- and patient-dependent
Longer term	Persistence, maintenance, and retreatment are not guaranteed from an ingredient acronym

Use standardized baseline documentation so that memory and changing lighting do not become the main outcome measures.

The immediate vs delayed framework provides product-system language for explaining these phases.

Cover alternatives and uncertainty

Consent should include reasonable alternatives and no treatment. Explain when another modality has a more direct relationship to the objective, when staged treatment reduces interpretive uncertainty, and when evidence for a requested area or use is limited.

Separate:

approved product information
published clinical technique
expert consensus
common off-label practice
manufacturer marketing claims

The regional regulation map provides the dated US, EU, and Korean evidence needed to make that distinction product-specific.

Material risks to discuss

Risk language should be proportionate and understandable. It should include expected short-term effects and uncommon but important complications:

pain, tenderness, bruising, redness, itching, and swelling
asymmetry, contour irregularity, visibility, or palpability
early or delayed nodules and inflammatory reactions
infection and draining lesions
tissue ischemia or necrosis
rare visual impairment, blindness, stroke-like events, and other neurologic injury
persistence of an unwanted result and limitations of removal

The FDA describes filler injection as a medical procedure and notes that vascular injection can cause necrosis, blindness, or stroke; it also notes that removal may be difficult or impossible for materials other than many HA fillers (FDA dermal-filler safety information 🔗).

Recent UK multidisciplinary guidance recommends that vision loss and stroke be described as rare but material risks during consent for soft-tissue fillers (UK vision-loss consensus 🔗).

Give actionable follow-up instructions

Provide written, product-appropriate instructions that distinguish:

expected short-term effects
findings that require prompt clinic review
symptoms that require immediate emergency action

Visual change, ocular pain, double vision, eyelid or eye-movement abnormality, sudden severe headache, neurologic deficit, or evolving ischemic skin change should not wait for a routine reply. Link the patient instructions to the clinic’s vascular and visual emergency pathway.

Record the product, indication and off-label status, alternatives, expected phases, material risks, removal limitations, follow-up plan, emergency route, patient questions, and decision. Reconfirm consent if the product, area, plan, or material circumstances change.